In randomized trials, intermittent fasting produced about the same weight loss as ordinary calorie reduction. On a GLP-1 medication, which already lowers intake, adding a fasting window can make it harder to eat enough protein, so discuss it with your prescriber first.
Intermittent fasting can work for weight loss, but in head-to-head randomized trials it has not beaten ordinary daily calorie reduction. Its main advantage is that some people find a fixed eating window easier to follow. If you take a GLP-1 medication, your appetite and intake are already lower, so a fasting window adds a second restriction on top of the first. That can make it harder to eat enough protein and nutrients, and for people on insulin or certain other diabetes medications it may raise the risk of low blood sugar. Talk with your prescriber before combining the two.
The National Institute on Aging (NIA) describes several patterns that are often grouped together:
| Pattern | How it works |
|---|---|
| Time-restricted eating | All meals within a set window, such as 6 to 8 hours each day |
| Alternate-day fasting | Unrestricted eating every other day, with no or minimal calories on the days in between |
| 5:2 pattern | Unrestricted eating 5 days a week, restricted calories on 2 days |
| Periodic fasting | Restricted calories for several days in a row, such as 5 days once a month |
The NIA notes that a practical effect of fasting may simply be fewer calories, because there is less time for eating. It also states that most human trials have been short and focused on weight loss, and that there is not yet enough evidence to recommend any such eating regimen to the public.
Three well designed randomized trials are especially useful because they compared fasting with a fair alternative rather than with no change at all.
Time-restricted eating plus calorie restriction (NEJM, 2022). Liu and colleagues randomized 139 adults with obesity in China to calorie restriction alone or the same calorie target eaten only between 8 a.m. and 4 p.m. After 12 months, average weight loss was 8.0 kg in the eating-window group and 6.3 kg in the calorie-restriction group. The difference was not statistically significant, and results for waist size, body fat, lean mass and metabolic risk factors pointed the same way. Adverse events did not differ substantially.
16:8 eating on its own (JAMA Internal Medicine, 2020). In the TREAT trial, Lowe and colleagues randomized 116 adults with overweight or obesity to eat only between noon and 8 p.m., or to eat three structured meals a day, for 12 weeks. Weight change did not differ significantly between groups. In a subgroup that had body composition scans, the eating-window group lost a significant amount of lean mass, and the difference in appendicular lean mass (arms and legs) between groups was significant. The authors concluded that time-restricted eating, in the absence of other interventions, was not more effective than eating throughout the day, and suggested future research on protein intake.
Alternate-day fasting (JAMA Internal Medicine, 2017). Trepanowski and colleagues compared alternate-day fasting with daily calorie restriction and a no-intervention control in 100 adults with obesity for one year. Weight loss relative to control was 6.0 percent with alternate-day fasting and 5.3 percent with daily restriction, which was not a meaningful difference. Dropout was highest in the fasting group (38 percent versus 29 percent), and fasting participants tended to eat more than prescribed on fast days and less on feast days. LDL cholesterol was higher at 12 months in the fasting group than in the daily restriction group.
Taken together, these trials suggest the eating pattern matters less than the total amount eaten and how well you can sustain it. Results are averages, and individual experiences vary.
The trials above were not designed to study people taking GLP-1 medications. Combining the two raises a few specific issues.
You are already eating less. In a 20-week trial in Diabetes, Obesity and Metabolism, calorie intake at a buffet-style lunch was 35 percent lower with semaglutide than with placebo, alongside less hunger and fewer cravings. When appetite is already low, a short eating window can squeeze out meals you actually need.
Protein and lean mass. The Lowe trial raised a flag about lean mass loss with time-restricted eating. A 2024 review in Obesity by Almandoz and colleagues on nutrition during antiobesity medication treatment recommends that clinicians counsel patients on protein, fiber, micronutrient and fluid intake, and monitor for inadequate intake. Fitting enough protein into one or two small meals is genuinely difficult. Our protein calculator can help you estimate a target, and our guide to protein and muscle during weight loss explains why it matters.
Low blood sugar with certain medications. The semaglutide label warns that the risk of hypoglycemia is higher when it is used with insulin or an insulin secretagogue such as a sulfonylurea. Long fasting periods on top of those medications should only happen with a plan from your prescriber.
Disordered eating risk. The National Institute of Diabetes and Digestive and Kidney Diseases notes that for some people, dieting in unhealthy ways, such as skipping meals or not eating enough, may contribute to binge eating. If you have a history of disordered eating, rigid fasting rules deserve extra caution.
A gentle, structured approach tends to be easier to sustain than an aggressive one:
There is no good evidence that it does. Trials that were not focused on medication users found that fasting patterns led to similar weight loss as regular calorie reduction. On a GLP-1 medication, the bigger risk is eating too little protein and too few nutrients.
It may be reasonable for some people, but safety depends on your health, your other medications and how much you are able to eat. People on insulin or sulfonylureas, and people with a history of disordered eating, should not start fasting without guidance.
It can if protein and resistance exercise are not maintained. In a 2020 trial of 16:8 eating, the eating-window group lost more lean mass in the arms and legs than the comparison group. This is one reason nutrition reviews emphasize protein and physical activity during weight loss; see our guide to strength training during weight loss.
A licensed provider can help you decide whether a structured eating window fits your medication plan, your blood sugar risk and your nutrition needs, and can adjust the plan if side effects or low intake become a problem. Medication dosing is always set by the prescriber. Explore our weight loss programs to learn more. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
Every weight loss method eventually levels off. The physiology behind plateaus, why GLP-1 medications delay them, and how to tell a true plateau from ordinary fluctuation.
Read articleWhen appetite drops, the quality of each meal matters more. A practical guide to protein, fiber, fluids and micronutrients while taking a GLP-1 medication, drawn from published clinical guidance.
Read articleThe first weeks on a GLP-1 usually mean a low starting dose that your prescriber raises gradually, a quieter appetite, and for many people mild to moderate digestive side effects. Knowing what is common and what to report makes the start easier.
Read article